Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Glatiramer in the treatment of multiple sclerosis Rizvi SA; Kim E; Moodie JInt J Nanomedicine 2006[]; 1 (3): 283-9Multiple sclerosis (MS) is a disease of the central nervous system with both an inflammatory and degenerative component. The disease primarily affects young adults and results in significant physical and cognitive disability. Several disease-modifying agents are currently used in the management of multiple sclerosis. Glatiramer acetate (GA, Copaxone, co-polymer 1) is a disease-modifying agent approved for the treatment of relapsing remitting multiple sclerosis. Apart from its unique mode of action, there is evidence pointing toward a possible neuroprotective role. This review will critically discuss GA's potential mechanisms of action, the results of clinical trials, safety profile, and future directions of treatment.|Clinical Trials as Topic[MESH]|Glatiramer Acetate[MESH]|Humans[MESH]|Immunosuppressive Agents/administration & dosage/adverse effects[MESH]|Models, Immunological[MESH]|Multiple Sclerosis/*drug therapy/*immunology[MESH]|Neuroprotective Agents/*administration & dosage/adverse effects[MESH]|Peptides/*administration & dosage/adverse effects[MESH]|Secondary Prevention[MESH] |
